Showing results (121-130 of 212) with videos related to
Sort By:
Pageof 22
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2023
Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists GuidelinePraveen Vikas, Hans Messersmith, Carolyn Compton, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 19, 2018
Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With ImmunotherapyChristine M Parseghian, Madhavi Patnana, Priya Bhosale, et al.Oncotarget|July 16, 2016
MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenonKanwal Raghav, Van Morris, Chad Tang, et al.Langenbeck'S Archives of Surgery|February 28, 2023
Prognostic significance of acellular mucin in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for appendiceal neoplasmsDerek J Erstad, Kristen A Robinson, Karen Beaty, et al.European Journal of Cancer (Oxford, England : 1990)|January 19, 2024
Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluationRomain Cohen, Morteza Raeisi, Benoist Chibaudel, et al.Journal for Immunotherapy of Cancer|May 31, 2024
Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 studyMichael J Overman, Fabio Gelsomino, Massimo Aglietta, et al.Cancer|March 12, 2019
Clinical and molecular characterization of early-onset colorectal cancerAlexandra N Willauer, Yusha Liu, Allan A L Pereira, et al.Nature Reviews. Cancer|February 20, 2025
Defining a 'cells to society' research framework for appendiceal tumoursAndreana N Holowatyj, Michael J Overman, Konstantinos I Votanopoulos, et al.JCO Precision Oncology|October 12, 2023
Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA TestingStefania Napolitano, Aparna R Parikh, Jason Henry, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistanceScott Kopetz, Paulo M Hoff, Jeffrey S Morris, et al.Pageof 22